Document is current
Any future updates will be listed below
-
Authors
Nomura, Masashi https://orcid.org/0000-0001-6095-7849
Raviram, Ramya
Schiffman, Joshua S. https://orcid.org/0000-0002-1028-1438
Bussema, Lillian https://orcid.org/0000-0001-5469-3816
Lu, Vivian
Wheeler, Noelle
Lee, John J. Y.
Fan, Yilin
Zheng, Mian Hua
Ruiz, Florian
Danish, Husain
Kellett, Sorcha
Nusrat, Labeeba
Chaligne, Ronan https://orcid.org/0000-0003-4332-3291
Huse, Jason T. https://orcid.org/0000-0003-4514-0640
Yung, W. K. Alfred https://orcid.org/0000-0002-1669-0793
Tanaka, Shota
Saito, Nobuhito
Das, Sunit
Potenski, Catherine
Landau, Dan A. https://orcid.org/0000-0003-2346-9541
Suvà, Mario L. https://orcid.org/0000-0001-9898-5351
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1HG011014)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA258763)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA245523)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA276765)
- License Information
-
More Information
Article History
Received: 8 March 2025
Accepted: 21 May 2026
First Online: 22 June 2026
Competing interests
: M.L.S. is an equity holder, scientific co-founder and advisory board member of Immunitas Therapeutics. The author declares that such activities have no relationship to the present study. D.A.L. has served as a consultant for AbbVie, AstraZeneca and Illumina and is on the Scientific Advisory Board of Mission Bio, Pangea, Alethiomics, Montage Bio and Veracyte; D.A.L. has received prior research funding from BMS, 10x Genomics, Ultima Genomics and Illumina unrelated to the current paper. R.C. is a consultant for Sanavia Oncology, LevitasBio and Precision Cell Systems. All other authors declare no competing interests.
